Ambroxol for Lewy body dementia to slow disease changes
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This early-stage study tests whether ambroxol can act as a “disease-modifying” treatment for Lewy body dementia, meaning it aims to change how the illness progresses rather than only relieve symptoms. You may be asked to complete brain testing and have stable medications while the study monitors memory, thinking, and safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been told you likely have Lewy body dementia
- You are over 50 years old
- Your MoCA thinking test score is between 18 and 24
- You have a caregiver who can help at least 4 days per week
- You can have brain scans (MRI and a DAT-scan) without safety issues (for example, no metal in eyes/head or pacemaker-type devices)
- Your Parkinson and dementia-related medicines have been on a stable dose for at least 3 months before starting
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial follows people with probable Lewy body dementia over several years to see how the brain changes on MRI and on memory/thinking tests. It may help researchers understand disease progression and improve future care for Lewy body dementia.
This study looks at how brain function changes over time in people with Lewy body disease or Alzheimer's. Researchers will use memory tests, MRI scans, and EEG (a painless brain-wave recording) to track these changes, and you will need a family member or friend to help report on your daily life.
This study tests donanemab, an investigational drug designed to target amyloid proteins in the brain that may contribute to cognitive decline in people with early dementia with Lewy bodies. The trial aims to see if this treatment can slow cognitive decline and help preserve thinking and memory.
This study helps people understand a protein called alpha-synuclein that may be related to memory problems and movement disorders. Researchers will either test your spinal fluid or skin to look for this protein, then discuss the results with you and measure how you're doing over time.
This trial tests whether ambroxol (a mouth medicine) can help people with new or early dementia with Lewy bodies (DLB) or mild cognitive impairment linked to DLB. Participants take the medicine for about 18 months while the study tracks safety and changes over time.
This study tests an eHealth program together with a patient-and-caregiver support program, along with a medicine called ambroxol. It aims to see whether this combined approach is safe and helpful for people with dementia with Lewy bodies (or early memory changes from it).
Hear when a new Lewy Body Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.